Processa pharmaceuticals regains compliance with nasdaq minimum bid price rule

Hanover, md, feb. 06, 2024 (globe newswire) -- processa pharmaceuticals, inc. (nasdaq: pcsa) (“processa” or the “company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for more patients suffering from cancer, announces it has received notice from the nasdaq stock market llc (“nasdaq”) informing the company that it has regained compliance with the minimum bid price requirement under nasdaq listing rule 5550(a)(2) (the “rule”) for continued listing on the nasdaq market and that the matter is now closed.
PCSA Ratings Summary
PCSA Quant Ranking